GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioverativ Inc (NAS:BIVV) » Definitions » Cost of Goods Sold

Bioverativ (Bioverativ) Cost of Goods Sold : $280 Mil (TTM As of Dec. 2017)


View and export this data going back to 2017. Start your Free Trial

What is Bioverativ Cost of Goods Sold?

Bioverativ's cost of goods sold for the three months ended in Dec. 2017 was $70 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2017 was $280 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Bioverativ's Gross Margin % for the three months ended in Dec. 2017 was 78.61%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Bioverativ's Inventory Turnover for the three months ended in Dec. 2017 was 1.98.


Bioverativ Cost of Goods Sold Historical Data

The historical data trend for Bioverativ's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioverativ Cost of Goods Sold Chart

Bioverativ Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17
Cost of Goods Sold
0.40 34.70 52.90 237.90 279.60

Bioverativ Quarterly Data
Dec13 Dec14 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.70 63.30 80.50 65.50 70.30

Bioverativ Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $280 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioverativ  (NAS:BIVV) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Bioverativ's Gross Margin % for the three months ended in Dec. 2017 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(328.7 - 70.3) / 328.7
=78.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Bioverativ's Inventory Turnover for the three months ended in Dec. 2017 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Bioverativ Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Bioverativ's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioverativ (Bioverativ) Business Description

Traded in Other Exchanges
N/A
Address
Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Brian S Posner director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John Cox director, officer: Chief Executive Officer C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
John Greene officer: EVP, CFO and Treasurer 51 LIME STREET, LONDON X0 EC3M 7DQ
Geno J Germano director 5 GIRALDA FARMS, MADISON NJ 07940
Louis J Paglia director C/O UIL HOLDINGS CORP, 157 CHURCH STREET, NEW HAVEN CT 06506
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Diantha Duvall officer: Chief Accounting Officer C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Vivaldi Coelho Rogerio officer: EVP, Chief Global Therapeutics 225 SECOND AVENUE, WALTHAM MA 02451
Harris Timothy J.r. officer: EVP, R & D C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451
Lucia Celona officer: EVP, HR & Corp Commun. Officer BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Richard Brudnick officer: EVP, Business Development BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142

Bioverativ (Bioverativ) Headlines

From GuruFocus

Jeff Ubben Buys 1, Sells 1 in 1st Quarter

By Sydnee Gatewood Sydnee Gatewood 05-24-2017

Seeking Value in Biotech: Bioverativ

By Mark Yu Mark Yu 06-29-2017

5 Companies Hit 52-Week Highs

By yifan900 yifan900 05-29-2018